FDA plans study on barriers to women's enrollment in pregnancy exposure registries and announces PRV fee rates

The Food and Drug Administration said it will conduct research into perceived barriers that limit women’s participation in pregnancy exposure registries.

It also released the fee schedule for priority review vouchers that will apply in the next fiscal year.

In addition, the agency named permanent leaders to three of its product centers.